PF-06260933
CAS No. : 1811510-56-1
| Size | Price | Stock |
|---|---|---|
| 5mg | $144 | In-stock |
| 10mg | $228 | In-stock |
| 25mg | $427 | In-stock |
| 50mg | $620 | In-stock |
| 100mg | $900 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-19562 |
| M.Wt: | 296.75 |
| Formula: | C16H13ClN4 |
| Purity: | >98 % |
| Solubility: | DMSO : 30 mg/mL (ultrasonic;warming) |
PF-06260933 is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively. IC50 & Target: IC50: 3.7 nM (MAP4K4 for Kinase), 160 nM (MAP4K4 for Cell)[1] In Vitro: PF-06260933 treatment of human aortic endothelial cell (EC) robustly prevents TNF-α-mediated endothelial permeability in vitro, similar to MAP4K4 knockdown[2]. In Vivo: In the mice model, PF-06260933 treatment does not alter plasma lipid content, although reductions in glucose levels are observed, which is consistent with whole-body-inducible Map4k4 knockout animals. PF-06260933 administration ameliorates further plaque development and/or promotes plaque regression in this animal model (46.0% versus 25.5%), and a reduction in plasma glucose as well as lipid content is also observed[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- PF-06260933
- Cat. No.:
- HY-19562
- Quantity:
Your information is safe with us.